Drugs and therapies – Page 13
-
ArticleBiotech leader champions targeted cancer treatments and diversity
Driven by a passion for innovation and inclusivity, Dr Catherine Pickering, CEO of iOnctura, is on a mission to transform cancer treatment while championing diversity within the biotech industry.
-
Article
Women in STEM with Avideh Nazeri
Avideh Nazeri, Vice President of Clinical, Medical and Regulatory for Novo Nordisk UK, reflects on her journey through the world of STEM, highlighting the resilience and determination required to overcome biases and challenges along the way. She discusses how perseverance, collaboration and independent thinking have shaped her career, and offers ...
-
ArticleTargeting CD40 with bispecifics to outsmart tumours
Søren Bregenholt, Chief Executive Officer at Alligator Bioscience, elucidates how creating bispecific antibodies that target both tumour-specific antigens and CD40, a receptor on the immune system’s dendritic cells, is a new approach that aims to trick tumours into telling the immune system how best to attack.
-
ArticleLeveraging agonist antibodies to address immunological diseases
Therapeutic antibodies play a key role in addressing unmet medical needs. Here, Dr Judy Chou, CEO, President and Board Member of AltruBio, Inc, explains how agonist antibodies show potential as a novel therapeutic approach in immunological diseases, helping to mediate interactions between circulating immune cells and influencing the intensity and ...
-
ArticleThe essential role of recombinant phage display antibody libraries
The emergence of new antibody-based therapeutics, such as antibody-drug conjugates, alongside a continued drive towards alternatives to animal testing approaches, highlights the need for precise and sensitive tools enabling the identification and characterisation of the best drug candidates for clinical progression. Capable of keeping up with the evolving drug development ...
-
ArticleChemical choreography: orchestrating complex API syntheses
Small molecules are essential for developing effective medicines, but their structural complexity and material behaviour present difficulties. In this article, Chris Brown, Senior Chemist, Onyx Scientific Ltd, discusses how the right technologies and approaches can enhance drug development and mitigate risk from initial phase to commercial launch.
-
ArticleWomen in STEM with Veerle d’Haenens
We had the privilege of talking to Veerle d’Haenens, General Manager, Global Therapy Innovations at Terumo Blood and Cell Technologies. Her successful career has been driven by her creativity, expertise and passion, and she advises women who are aspiring to STEM roles to always think big.
-
ReportBeyond the lab: antibodies
Amidst a new wave of innovation in antibody research, this report highlights recent breakthroughs across fields such as cancer research and neuroscience, showcasing how advancements are redefining the precision and potential of antibody-based therapies.
-
ArticleUnlocking a new molecular space in rapid drug discovery
So-called undruggable pharmaceutical targets could be tackled with intermediate sized drugs such as macrocycles, combining the advantages of small molecules and biologics. The preparation of very large libraries of chemically synthesised intermediate-sized molecules is now in reach with a new technology developed at ETH Zurich. In this article, Dr Michelle ...
-
ArticleHighlights of the AAPS 2024 Summer Scientific Forum
In this episode, we discuss the history of the AAPS Summer Scientific Forum, highlights from the 2024 event, and its goals for the future.
-
ArticleHarnessing the CD24/Siglec-10 pathway: immunotherapy innovation
Renowned immunologist Dr Yang Liu shares his insights into the preclinical studies behind the development of drug candidates targeting the CD24/Siglec-10 pathway. He discusses the technical and regulatory hurdles of antibody development, how these therapies compare to existing immunotherapies, and the potential for personalised cancer treatment through biomarker development.
-
ArticleWomen in STEM with Cristina de Min
Driven by a passion for early-stage scientific discovery, Cristina de Min, MD, Chief Medical Officer at Topas Therapeutics, transitioned from clinical practice to drug development. Her expertise has played a pivotal role in advancing new treatments, with her achievements demonstrating her commitment to improving patient outcomes.
-
ArticleThe hidden risks of over-reliance on healthy donor material
Developing cell therapies solely with healthy donor material can jeopardise clinical outcomes, introducing risks ranging from faulty preclinical data to manufacturing failures. We spoke to Priya Baraniak, CBO at OrganaBio, who advocates for early integration of diseased donor material, improved biobanking infrastructure, and cross-industry collaboration to develop more effective, patient-relevant ...
-
ArticleCombining precision bispecific antibodies with targeted radiotherapy
Radioimmunotherapy (RIT) is a promising cancer treatment gaining recognition in precision oncology. It utilises radiolabelled antibodies to deliver targeted radiation to tumours, with success in hematologic cancers. However, its use in solid tumours has been limited by off-target radiation and toxicity, with few clinical trials advancing beyond phase II. Alexander ...
-
ArticleCell and gene therapy development moves into cardiac indications
The success of CAR-Ts in oncology has stoked enthusiasm for developing comparable curative therapies in other disease areas. CellProthera’s Chief Scientific Officer, Ibon Garitaonandia, explains the potential and progress for CGTs in cardiology, where disease-modifying therapies are largely non-existent.
-
ArticleUnlocking the potential of smart antibodies
Biolojic Design is redefining antibody therapies by creating “programmable” antibodies that intelligently target well-validated autoimmune and oncology pathways. In this Q&A, CEO and founder Yanay Ofran, PhD, describes Biolojic’s groundbreaking approach, which leverages AI and machine learning to design antibodies capable of adjusting their behaviour based on their biological environment. ...
-
ArticleScaling genetic medicine with tRNA
Tune into this episode which explores how engineered tRNAs could treat thousands of rare diseases and cancers that share the same mutation.
-
ArticleAI-driven drug discovery: insights from Cresset
In this in-depth Q&A, Mutlu Dogruel, Vice President of AI at Cresset shares his insights surrounding chatbots, retrieval augmented generation and AI hallucinations, to open up new possibilities for innovation in pharmaceutical research.
-
Article
Looking beyond traditional oncogenic pathways to break cancer resistance
Drug resistance is the leading cause of poor clinical outcomes for cancer patients undergoing targeted therapies. While current treatments are designed to inhibit targets along established oncogenic signalling cascades, a new, exciting approach is to address non-oncogene-related resistance mechanisms that operate in parallel to the “classic” oncogene pathways. Blocking transcriptional ...
-
Article
Part four: an industry leader’s perspective on managing data quality
In this four-part series, Dr Raminderpal Singh discusses the challenges surrounding limited data quality and offers some pragmatic solutions. In this fourth article, he talks to John Conway, Chief Visioneer Officer at 20/15 Visioneers for an expert perspective.